Hepatocellular adenoma secondary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Hepatocellular adenoma}} | {{Hepatocellular adenoma}} | ||
{{CMG}}; {{AE}}{{ | {{CMG}}; {{AE}}{{ZAS}} | ||
==Overview== | ==Overview== | ||
An yearly followup with MRI or ultrasound may be scheduled for female patients until menopause. | An yearly followup with MRI or ultrasound may be scheduled for female patients until menopause. | ||
Revision as of 14:34, 14 January 2019
|
Hepatocellular adenoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hepatocellular adenoma secondary prevention On the Web |
|
American Roentgen Ray Society Images of Hepatocellular adenoma secondary prevention |
|
Risk calculators and risk factors for Hepatocellular adenoma secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Zahir Ali Shaikh, MD[2]
Overview
An yearly followup with MRI or ultrasound may be scheduled for female patients until menopause.
Hepatocellular adenoma secondary prevention
- An yearly followup with MRI or ultrasound may be scheduled for female patients until menopause, when the adenoma is < 5cm or regress to < 5cm after discontinuation of oral contracepative medications.[1]
References
- ↑ Maarten G. Thomeer, Mirelle Broker, Joanne Verheij, Michael Doukas, Turkan Terkivatan, Diederick Bijdevaate, Robert A. De Man, Adriaan Moelker & Jan N. IJzermans (2016). "Hepatocellular adenoma: when and how to treat? Update of current evidence". Therapeutic advances in gastroenterology. 9 (6): 898–912. doi:10.1177/1756283X16663882. PMID 27803743. Unknown parameter
|month=ignored (help)